CYP11B1 | Cytochrome P450, family 11, subfamily B, polypeptide 1 | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins
| | | | | Tissue enriched |
CYP11B2 | Cytochrome P450, family 11, subfamily B, polypeptide 2 | Disease related genes Enzymes Mitochondrial proteins Potential drug targets
| | | | | Tissue enriched |
HSD3B2 | Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Predicted membrane proteins
| | | | | Tissue enriched |
CYP21A2 | Cytochrome P450, family 21, subfamily A, polypeptide 2 | Disease related genes Enzymes Plasma proteins Potential drug targets Predicted secreted proteins
| | | | | Tissue enriched |
SELM | Selenoprotein M | Predicted secreted proteins
| | | | | Tissue enriched |
AC015660.1 | HCG1993240; Serologically defined breast cancer antigen NY-BR-40; Uncharacterized protein | | | | | | Tissue enriched |
MC2R | Melanocortin 2 receptor (adrenocorticotropic hormone) | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC24A2 | Solute carrier family 24 (sodium/potassium/calcium exchanger), member 2 | Predicted membrane proteins Transporters
| | | | | Group enriched |
TH | Tyrosine hydroxylase | Disease related genes Enzymes FDA approved drug targets
| | | | | Tissue enriched |
NXPH1 | Neurexophilin 1 | Predicted secreted proteins
| | | | | Group enriched |
NOV | Nephroblastoma overexpressed | Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
CAMK2N2 | Calcium/calmodulin-dependent protein kinase II inhibitor 2 | | | | | | Group enriched |
MRAP | Melanocortin 2 receptor accessory protein | Disease related genes Predicted membrane proteins
| | | | | Group enriched |
ARHGAP36 | Rho GTPase activating protein 36 | Predicted secreted proteins
| | | | | Tissue enriched |
FAM19A3 | Family with sequence similarity 19 (chemokine (C-C motif)-like), member A3 | Predicted secreted proteins
| | | | | Group enriched |
LSP1 | Lymphocyte-specific protein 1; Uncharacterized protein | | | | | | Group enriched |
LRRC38 | Leucine rich repeat containing 38 | Predicted membrane proteins
| | | | | Group enriched |
CYP17A1 | Cytochrome P450, family 17, subfamily A, polypeptide 1 | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
C1orf111 | Chromosome 1 open reading frame 111 | | | | | | Group enriched |
FAM166B | Family with sequence similarity 166, member B | | | | | | Group enriched |
TUBB4A | Tubulin, beta 4A class IVa | Disease related genes Plasma proteins
| | | | | Group enriched |
FNDC9 | Fibronectin type III domain containing 9 | Predicted membrane proteins
| | | | | Group enriched |
NSG2 | Neuron-specific protein family member 2 | Predicted membrane proteins
| | | | | Group enriched |
PNMT | Phenylethanolamine N-methyltransferase | Cancer-related genes Enzymes Plasma proteins
| | | | | Tissue enriched |
ASB4 | Ankyrin repeat and SOCS box containing 4 | | | | | | Group enriched |
CNTNAP5 | Contactin associated protein-like 5 | Predicted membrane proteins
| | | | | Group enriched |
PHOX2A | Paired-like homeobox 2a | Disease related genes Transcription factors
| | | | | Tissue enriched |
PRLHR | Prolactin releasing hormone receptor | G-protein coupled receptors Predicted membrane proteins
| | | | | Group enriched |
CALY | Calcyon neuron-specific vesicular protein | FDA approved drug targets Predicted membrane proteins
| | | | | Group enriched |
CHGB | Chromogranin B (secretogranin 1) | Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
DRGX | Dorsal root ganglia homeobox | Transcription factors
| | | | | Tissue enriched |
FSTL5 | Follistatin-like 5 | Predicted secreted proteins
| | | | | Group enriched |
NPY | Neuropeptide Y | Plasma proteins Predicted secreted proteins
| | | | | Group enriched |
SEZ6L | Seizure related 6 homolog (mouse)-like | Predicted membrane proteins
| | | | | Group enriched |
VWA5B2 | Von Willebrand factor A domain containing 5B2 | Predicted secreted proteins
| | | | | Tissue enriched |
C18orf42 | Chromosome 18 open reading frame 42 | | | | | | Tissue enriched |
CDH18 | Cadherin 18, type 2 | Predicted membrane proteins Predicted secreted proteins
| | | | | Group enriched |
TFAP2B | Transcription factor AP-2 beta (activating enhancer binding protein 2 beta) | Cancer-related genes Disease related genes Plasma proteins Transcription factors
| | | | | Group enriched |
DLK1 | Delta-like 1 homolog (Drosophila) | Predicted membrane proteins Predicted secreted proteins
| | | | | Group enriched |
INA | Internexin neuronal intermediate filament protein, alpha | | | | | | Group enriched |
KCNQ2 | Potassium voltage-gated channel, KQT-like subfamily, member 2 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
CPLX2 | Complexin 2 | | | | | | Group enriched |
FAM19A4 | Family with sequence similarity 19 (chemokine (C-C motif)-like), member A4 | Predicted secreted proteins
| | | | | Tissue enriched |
PPP1R17 | Protein phosphatase 1, regulatory subunit 17 | | | | | | Group enriched |
SYT14 | Synaptotagmin XIV | Disease related genes Predicted membrane proteins
| | | | | Group enriched |
UNC5A | Unc-5 homolog A (C. elegans) | Predicted membrane proteins
| | | | | Group enriched |
DBH | Dopamine beta-hydroxylase (dopamine beta-monooxygenase) | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
GCGR | Glucagon receptor | FDA approved drug targets G-protein coupled receptors Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Group enriched |
FAM163B | Family with sequence similarity 163, member B | Predicted membrane proteins
| | | | | Group enriched |
FDX1 | Ferredoxin 1 | Mitochondrial proteins
| | | | | Tissue enriched |